BackAbbott Laboratories Overview

Abbott Laboratories Total Liabilities

Track Abbott Laboratories's total liabilities ($58B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$57.73B
22717.39% YoYΔ $57.48B vs prior year quarter

Peer average

Loading

Abbott Laboratories Total Liabilities History

Loading

Abbott Laboratories vs. peers: Total Liabilities Comparison

Loading

Abbott Laboratories Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Abbott Laboratories (ABT) FAQ

Abbott Laboratories's total liabilities stands at $58B as of March 2026. That compares with $250M in the prior-year period — up 22717.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Abbott Laboratories reported $58B in total liabilities versus $250M a year earlier — a 22717.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $250M in the prior-year period — up 22717.4% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Abbott Laboratories's total liabilities evolved across reporting periods, while the comparison chart places ABT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Abbott Laboratories's reading of $58B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.